This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
4nj3
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | + | ==Modulating the interaction between CDK2 and Cyclin A with a Quinoline-based inhibitor== | |
| - | + | <StructureSection load='4nj3' size='340' side='right' caption='[[4nj3]], [[Resolution|resolution]] 1.85Å' scene=''> | |
| - | { | + | == Structural highlights == |
| + | <table><tr><td colspan='2'>[[4nj3]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NJ3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4NJ3 FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2KD:6-(3-CHLOROPHENYL)-2-{[(2S)-3-(4-HYDROXYPHENYL)-1-METHOXY-1-OXOPROPAN-2-YL]CARBAMOYL}QUINOLINE-4-CARBOXYLIC+ACID'>2KD</scene></td></tr> | ||
| + | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene>, <scene name='pdbligand=CSD:3-SULFINOALANINE'>CSD</scene></td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CDK2, CDKN2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
| + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Cyclin-dependent_kinase Cyclin-dependent kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.22 2.7.11.22] </span></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4nj3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4nj3 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4nj3 RCSB], [http://www.ebi.ac.uk/pdbsum/4nj3 PDBsum]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | A new class of quinoline-based kinase inhibitors has been discovered that both disrupt cyclin dependent 2 (CDK2) interaction with its cyclin A subunit and act as ATP competitive inhibitors. The key strategy for discovering this class of protein-protein disrupter compounds was to screen the monomer CDK2 in an affinity-selection/mass spectrometry-based technique and to perform secondary assays that identified compounds that bound only to the inactive CDK2 monomer and not the active CDK2/cyclin A heterodimer. Through a series of chemical modifications the affinity (Kd) of the original hit improved from 1 to 0.005muM. | ||
| - | + | Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.,Deng Y, Shipps GW Jr, Zhao L, Siddiqui MA, Popovici-Muller J, Curran PJ, Duca JS, Hruza AW, Fischmann TO, Madison VS, Zhang R, McNemar CW, Mayhood TW, Syto R, Annis A, Kirschmeier P, Lees EM, Parry DA, Windsor WT Bioorg Med Chem Lett. 2014 Jan 1;24(1):199-203. doi: 10.1016/j.bmcl.2013.11.041. , Epub 2013 Nov 23. PMID:24332088<ref>PMID:24332088</ref> | |
| - | + | ||
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | == | + | ==See Also== |
| - | + | *[[Cell division protein kinase 2|Cell division protein kinase 2]] | |
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Cyclin-dependent kinase]] | [[Category: Cyclin-dependent kinase]] | ||
[[Category: Human]] | [[Category: Human]] | ||
| - | [[Category: Fischmann, T O | + | [[Category: Fischmann, T O]] |
| - | [[Category: Hruza, A W | + | [[Category: Hruza, A W]] |
[[Category: Atp-binding]] | [[Category: Atp-binding]] | ||
[[Category: Cancer]] | [[Category: Cancer]] | ||
[[Category: Cell cycle]] | [[Category: Cell cycle]] | ||
[[Category: Cell division]] | [[Category: Cell division]] | ||
| - | [[Category: Cyclin-dependent kinase]] | ||
[[Category: Inhibition]] | [[Category: Inhibition]] | ||
[[Category: Mitosis]] | [[Category: Mitosis]] | ||
Revision as of 18:00, 21 December 2014
Modulating the interaction between CDK2 and Cyclin A with a Quinoline-based inhibitor
| |||||||||||
